Cognition Therapeutics, Inc. Net Income (Loss) Available to Common Stockholders, Basic
Cognition Therapeutics, Inc. (CGTX) reported Net Income (Loss) Available to Common Stockholders, Basic of -$6.17 million for the 3-month period ending 2023-03-31, per its 10-Q filed 2023-05-04.
Discontinued › Income Statement
us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic · last filed 2023-05-04
- Cognition Therapeutics, Inc. net income (loss) available to common stockholders, basic for the quarter ending 2023-03-31 was -$6.17M.
- Cognition Therapeutics, Inc. net income (loss) available to common stockholders, basic for the quarter ending 2022-12-31 was -$5.18M.
- Cognition Therapeutics, Inc. net income (loss) available to common stockholders, basic for the quarter ending 2022-09-30 was -$6.63M.
- Cognition Therapeutics, Inc. net income (loss) available to common stockholders, basic for the quarter ending 2022-06-30 was -$5.75M.
- Cognition Therapeutics, Inc. net income (loss) available to common stockholders, basic for fiscal 2022 was -$21.40M.
- Cognition Therapeutics, Inc. net income (loss) available to common stockholders, basic for fiscal 2021 was -$16.25M.
- Cognition Therapeutics, Inc. net income (loss) available to common stockholders, basic for fiscal 2020 was -$12.07M.
| Period end | Net Income (Loss) Available to Common Stockholders, Basic 3 month | Net Income (Loss) Available to Common Stockholders, Basic 6 month | Net Income (Loss) Available to Common Stockholders, Basic 9 month | Net Income (Loss) Available to Common Stockholders, Basic 12 month |
|---|---|---|---|---|
| 2023-03-31 | -$6.17M 10-Q · filed 2023-05-04 | -$11.35M derived: sum of 2 quarters · filed 2023-05-04 | -$17.98M derived: sum of 3 quarters · filed 2023-05-04 | -$23.73M derived: sum of 4 quarters · filed 2023-05-04 |
| 2022-12-31 | -$5.18M derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-23 | -$11.81M derived: sum of 2 quarters · filed 2023-03-23 | -$17.56M derived: sum of 3 quarters · filed 2023-03-23 | -$21.40M 10-K · filed 2023-03-23 |
| 2022-09-30 | -$6.63M 10-Q · filed 2022-11-14 | -$12.38M derived: sum of 2 quarters · filed 2022-11-14 | -$16.21M 10-Q · filed 2022-11-14 | -$23.76M derived: sum of 4 quarters · filed 2023-05-04 |
| 2022-06-30 | -$5.75M 10-Q · filed 2022-08-09 | -$9.59M 10-Q · filed 2022-08-09 | -$17.14M derived: sum of 3 quarters · filed 2023-05-04 | -$22.10M derived: sum of 4 quarters · filed 2023-05-04 |
| 2022-03-31 | -$3.84M 10-Q · filed 2023-05-04 | -$11.38M derived: sum of 2 quarters · filed 2023-05-04 | -$16.35M derived: sum of 3 quarters · filed 2023-05-04 | -$19.18M derived: sum of 4 quarters · filed 2023-05-04 |
| 2021-12-31 | -$7.54M derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-23 | -$12.51M derived: sum of 2 quarters · filed 2023-03-23 | -$15.34M derived: sum of 3 quarters · filed 2023-03-23 | -$16.25M 10-K · filed 2023-03-23 |
| 2021-09-30 | -$4.97M 10-Q · filed 2022-11-14 | -$7.80M derived: sum of 2 quarters · filed 2022-11-14 | -$8.70M 10-Q · filed 2022-11-14 | -$11.63M derived: sum of 4 quarters · filed 2022-11-14 |
| 2021-06-30 | -$2.83M 10-Q · filed 2022-08-09 | -$3.73M 10-Q · filed 2022-08-09 | -$6.67M derived: sum of 3 quarters · filed 2022-08-09 | -$9.52M derived: sum of 4 quarters · filed 2022-08-09 |
| 2021-03-31 | -$905.00K 10-Q · filed 2022-05-11 | -$3.84M derived: sum of 2 quarters · filed 2022-05-11 | -$6.69M derived: sum of 3 quarters · filed 2022-05-11 | |
| 2020-12-31 | -$2.93M derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-30 | -$5.79M derived: sum of 2 quarters · filed 2022-03-30 | -$12.07M 10-K · filed 2022-03-30 | |
| 2020-09-30 | -$2.85M 10-Q · filed 2021-11-17 | -$9.14M 10-Q · filed 2021-11-17 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Pelthos Therapeutics Inc. (PTHS) | United States | $0.086B | -1.20 |
| Atara Biotherapeutics, Inc. (ATRA) | United States | $0.086B | -6.48 |
| Vaxart, Inc. (VXRT) | United States | $0.080B | 3.84 |
| Cardiff Oncology, Inc. (CRDF) | United States | $0.101B | -2.22 |
| Kalaris Therapeutics, Inc. (KLRS) | United States | $0.073B | -2.19 |
| Black Diamond Therapeutics, Inc. (BDTX) | United States | $0.109B | -2.48 |
| CHAMPIONS ONCOLOGY, INC. (CSBR) | United States | $0.070B | -68.02 |
| BioStem Technologies, Inc. (BSEM) | United States | $0.069B | |
| Eloxx Pharmaceuticals, Inc. (ELOX) | United States | $0.065B | |
| LENZ Therapeutics, Inc. (LENZ) | United States | $0.117B | -1.41 |